专题:Metabolism, Diabetes, and Cancer

This cluster of papers explores the role of AMP-activated protein kinase (AMPK) in regulating cellular metabolism, including its involvement in glucose and lipid metabolism, insulin signaling, mitochondrial homeostasis, and the potential impact on cancer risk. The cluster also delves into the mechanisms of action of metformin, a drug known to activate AMPK and its effects on cellular energy balance and gene expression regulation.
最新文献
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis

article Full Text OpenAlex

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

article Full Text OpenAlex

Multi-omics analysis of diabetic cardiomyopathy pathogenesis using a type 2 diabetic Zucker diabetic fatty rat model

article Full Text OpenAlex

Metformin slows intestinal glucose absorption in type 2 diabetes, irrespective of the timing of its administration

letter Full Text OpenAlex

Semaglutide in Adults with Type 1 Diabetes and Obesity

article Full Text OpenAlex

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy

article Full Text OpenAlex

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

article Full Text OpenAlex

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

article Full Text OpenAlex

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

article Full Text OpenAlex

Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo

article Full Text OpenAlex

近5年高被引文献
Once-Weekly Semaglutide in Adults with Overweight or Obesity

article Full Text OpenAlex 2980 FWCI400.228

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

article Full Text OpenAlex 1394 FWCI444.815

Cancer metabolism: looking forward

review Full Text OpenAlex 1380 FWCI36.767

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

article Full Text OpenAlex 1280 FWCI177.147

The hallmarks of cancer metabolism: Still emerging

review Full Text OpenAlex 915 FWCI37.938

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

article Full Text OpenAlex 906 FWCI119.641

The cancer metabolic reprogramming and immune response

review Full Text OpenAlex 873 FWCI22.202

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

article Full Text OpenAlex 861 FWCI94.266

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

review Full Text OpenAlex 739 FWCI35.187

The metabolism of cancer cells during metastasis

review Full Text OpenAlex 731 FWCI21.019